Eli Lilly Plans to File for Approval of Next-Generation Obesity Drug Retatrutide in 2027 Following Successful Trials
Eli Lilly plans to seek approval for its next-generation obesity drug, retatrutide, in early 2027 after successful late-stage trials, highlighting its potential to capture a significant share of the growing obesity and diabetes treatment market.